SAMRAT PHARMACHEM LTD. (SAMRATPH)

Newspaper Publication of Extract of the Standalone Audited Financial Results for the year ended March 31, 2026.

The Board considered and adopted the financial results for the quarter and year ended March 31, 2026

Audited Financial Results for the quarter and year ended 31st March, 2026

Annual Secretarial Compliance for the year ended 31-March-2026

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanySamrat Pharmachem Ltd- 2CIN NO.L24230GJ1992PLC017820 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY - 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Nishant Kankaria Designation: Company Secretary and Compliance Officer EmailId: contact@samratpharmachem.in Name of the Chief Financial Officer: Rajesh Mehta Designation: CFO EmailId: rajesh@samratpharmachem.com Date: 07/04/2026 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.